Preview Mode Links will not work in preview mode

This Week in Cardiology

Apr 1, 2022

Coronary CTA, semaglutide, coronary artery calcium, exercise, and an ACC and EHRA preview are the topics discussed by John Mandrola, MD, in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I – Coronary CTA Feedback

- Coronary Computed Tomography Angiography vs Functional Stress Testing for Patients With Suspected Coronary Artery Disease

II – Semaglutide

- FDA Okays Semaglutide Higher Dose, 2 mg/Week, for Type 2 Diabetes

- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

- Once-Weekly Semaglutide in Adults with Overweight or Obesity


- Calcium Scores Predict Sudden-Death Risk in Preclinical CAD in Large Cohort Study

- Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death: The Coronary Artery Calcium Consortium

IV – Exercise and COVID-19

- More Exercise Linked to Lower Chance of Severe COVID-19: Study

- Small steps, strong shield: directly measured, moderate physical activity in 65 361 adults is associated with significant protective effects from severe COVID-19 outcomes

V – ACC Preview

- Hybrid ACC.22 Resurrects the Live Scientific Session

- Mandrola Previews the 2022 American College of Cardiology Scientific Sessions

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact